Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Helsinn Group, the Swiss Group focused on building quality cancer care, today announces that the European Commission has endorsed the Committee for Medicinal Products for Human Use's Opinion recommending the approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients one month of age and older.

27 May 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.

22 May 2015

Scientists identify new molecules that destroy cancer cells, save healthy ones

Researchers have identified new molecules that kill cancer cells while protecting healthy cells and that could be used to treat a variety of different cancers. The research shines a light on what happens to cells at the moment they become cancerous.

15 May 2015

Transgender people at greater risk for eating disorders

Transgender and non-transgender lesbian, gay and bisexual students are at greater risk for eating disorders, finds a new study from the Brown School at Washington University in St. Louis and Washington University School of Medicine in St. Louis.

13 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Enhanced recovery program for patients undergoing colorectal operations speeds patients' recovery

Patients undergoing colorectal operations who participated in an enhanced recovery program left the hospital sooner and had significantly lower hospital costs than patients who had the traditional approach to their care, according to a new study, which also found further postoperative improvements after adding an infection prevention protocol.

8 May 2015

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

6 May 2015

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapies.

5 May 2015

Researchers reveal potential mode of drug resistance in malaria parasites

Scientists have uncovered a potential mode of parasite drug resistance in malaria infection, according to a report published in The Journal of Experimental Medicine.

5 May 2015

Plastic surgeons find association between carpal tunnel syndrome and migraine headache

Plastic surgeons at UT Southwestern Medical Center have demonstrated for the first time an association between migraines and carpal tunnel syndrome, with migraines more than twice as prevalent in those with carpal tunnel syndrome as those without, according to the study.

28 Apr 2015

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

NUH develops new treatment guidelines to support women suffering from Hyperemesis

Nottingham’s hospitals (NUH) is the first Trust in the country to develop a new treatment plan to support women suffering from severe sickness during pregnancy.

24 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma Ltd, the supportive care company developing products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard anti-emetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a clinically significant problem in patients undergoing surgery, despite the availability of a range of anti-emetic medications.

21 Apr 2015

Extreme morning sickness during pregnancy linked to developmental problems in children

Women who experience extreme morning sickness during pregnancy are three times more likely to have children with developmental issues, including attention disorders and language and speech delays, than woman who have normal nausea and vomiting, a UCLA study has found.

21 Apr 2015

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease to treat.

21 Apr 2015

New OCT angiography can improve clinical management of leading causes of blindness

Research published today in the Proceedings of the National Academy of Sciences demonstrates that technology invented by researchers at Oregon Health & Science University's Casey Eye Institute can improve the clinical management of the leading causes of blindness.

21 Apr 2015

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.

From Baxter International Inc. 16 Apr 2015

Vomiting News and Research

Further Reading

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Scientists identify new molecules that destroy cancer cells, save healthy ones

Transgender people at greater risk for eating disorders

Orexigen Therapeutics provides update on business and financial results for Q1 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Enhanced recovery program for patients undergoing colorectal operations speeds patients' recovery

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

Researchers reveal potential mode of drug resistance in malaria parasites

Plastic surgeons find association between carpal tunnel syndrome and migraine headache

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

NUH develops new treatment guidelines to support women suffering from Hyperemesis

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Extreme morning sickness during pregnancy linked to developmental problems in children

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

New OCT angiography can improve clinical management of leading causes of blindness

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News